Cargando…

Erratum: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model

Detalles Bibliográficos
Autores principales:	Kirouac, Daniel C., Schaefer, Gabriele, Chan, Jocelyn, Merchant, Mark, Orr, Christine, Huang, Shih-Min A., Moffat, John, Liu, Lichuan, Gadkar, Kapil, Ramanujan, Saroja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583384/ https://www.ncbi.nlm.nih.gov/pubmed/28879057 http://dx.doi.org/10.1038/s41540-017-0026-z

Ejemplares similares

Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model
por: Kirouac, Daniel C., et al.
Publicado: (2017)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Erratum to “Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanoma”
por: Ponti, Giovanni, et al.
Publicado: (2014)

BRAF(V600E) Immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells: A STROBE-Compliant Article: Erratum
Publicado: (2015)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2018)

Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
por: Gadkar, Kapil, et al.
Publicado: (2016)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
por: Robinson, Giles W, et al.
Publicado: (2014)

gQSPSim: A SimBiology‐Based GUI for Standardized QSP Model Development and Application
por: Hosseini, Iraj, et al.
Publicado: (2020)

A Six‐Stage Workflow for Robust Application of Systems Pharmacology
por: Gadkar, K, et al.
Publicado: (2016)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

gPKPDSim: a SimBiology(®)-based GUI application for PKPD modeling in drug development
por: Hosseini, Iraj, et al.
Publicado: (2018)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
por: Hosseini, Iraj, et al.
Publicado: (2020)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Reliability of BRAF mutation detection using plasma sample: A protocol for systematic review and meta-analysis: Erratum
Publicado: (2022)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Erratum: Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity
por: Pan, Yanchun, et al.
Publicado: (2016)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Erratum: Structural and Dynamic Features of F-recruitment Site Driven Substrate Phosphorylation by ERK2
por: Piserchio, Andrea, et al.
Publicado: (2015)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
por: Yang, Meijia, et al.
Publicado: (2017)

Erratum to “Hand Surgery Patient Perspectives on Medical Cannabis: A Survey of Over 600 Patients” [Journal of Hand Surgery Global Online 5 (2023) 102-107]
por: Fones, Lilah, et al.
Publicado: (2023)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
por: Sen, Shiraj, et al.
Publicado: (2020)

Erratum to: Averting the legacy of kidney disease: focus on childhood
por: Ingelfinger, Julie R., et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Erratum to: RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma
por: Zhao, Weilin, et al.
Publicado: (2017)

HGG-02. ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
por: Kimura, Yui, et al.
Publicado: (2020)

BRAF(V600E) Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
por: Soria, Xavier, et al.
Publicado: (2021)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023)

Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Publicado: (2020)

Erratum: aptf-1 mutants are primarily defective in head movement quiescence during C. elegans sleep
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_khh0q3drosujdpv9ijt36g5c9i